Delek Group’s Pfizer PFE Stock Holding History

Delek Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-85,992	Closed	-$2.85M	–	247
2018 Q2	$2.85M	Sell	85,992 -421	-0.5%	-$14.4K	0.12%	151
2018 Q1	$2.91M	Hold	86,413	–	–	0.15%	140
2017 Q4	$2.96M	Buy	+86,413	New	+$2.95M	0.16%	135

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Delek Group's PFE Position: Q3 2018 in Review

Delek Group sold out of Pfizer (PFE) in Q3 2018, closing a stake of 85,992 shares — an estimated $2.85M sold.

Delek Group first reported a position in PFE in Q4 2017 and held it in 3 quarters. The position peaked at $2.96M in Q4 2017. 2,256 funds tracked by Wall St. Rank hold PFE as of Q3 2018.

Delek Group reported no remaining Pfizer position as of Q3 2018 after selling out during the quarter.
Delek Group sold 85,992 Pfizer shares in Q3 2018, an estimated $2.85M.
Delek Group first reported a position in Pfizer in Q4 2017 and held it in 3 quarters.
Delek Group's Pfizer position peaked at $2.96M in Q4 2017.
2,256 funds tracked by Wall St. Rank held Pfizer as of Q3 2018.

Based on Delek Group's 13F filing for Q3 2018, filed 14 Nov 2018.